Table 1.

Overview of basic characteristics of CVOTs completed 2016/17 and published in 2017

	Study status	Drug	Drug class	Intervention	Primary outcome	N	Follow-up (years)	Start and end date	Clinicaltrials.gov ID
CANVAS program	Completed	Canagliflozin	SGLT-2 Inhibitor	Canagliflozin 100 mg vs. canagliflozin 300 mg vs. placebo	CV death, MI, or stroke	10,142	3.6	12.2009–02.2017	NCT01032629
EXSCEL	Completed	Exenatide	GLP-1 receptor agonist	Exenatide once-weekly vs. placebo	CV death, MI, or stroke	14,752	3.2	06.2010–04.2017	NCT01144338
DEVOTE	Completed	Insulin degludec	Basal insulins	Insulin degludec vs. Insulin glargine	CV death, MI, or stroke	7637	2.0	10.2013–10.2016	NCT01959529
ACE	Completed	Acarbose	α-glucosidase inhibitor	Acarbose vs. placebo	CV death, MI, or stroke, HHF,HUA	6522	5.0	02.2009–04.2017	NCT00829660
FOURIER	Completed	Evolocumab	PCSK9 inhibitor	Evolocumab vs. placebo	CV death, MI, stroke, UA or coronary revascularisation	27,564	2.2	01.2013–11.2016	NCT01764633